Literature DB >> 18707800

Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States.

Sareeta R S Parker1, Senait Dyson, Stacey Brisman, Michelle Pennie, Robert A Swerlick, Rizwana Khan, Sue Manos, Benjamin D Korman, Zongqi Xia, Neil J Korman.   

Abstract

BACKGROUND: There are large discrepancies in reported mortality for bullous pemphigoid (BP).
OBJECTIVE: We sought to determine the mortality of a large cohort of patients with BP and compare this with age-matched control subjects.
METHODS: Data were collected on 223 patients with a new diagnosis of BP between 1998 and 2003 through our cutaneous immunofluorescence laboratory databases. The mortality of patients with BP was compared with that of age-matched control subjects in the general US population.
RESULTS: The 1-, 2-, and 5-year mortality was 0.23 (95% confidence interval=0.18, 0.29), 0.37 (95% confidence interval=0.31, 0.44), and 0.50 (95% confidence interval=0.42, 0.57), respectively. However, relative to age-matched control subjects, no difference in expected mortality was detected. LIMITATIONS: This was a retrospective cohort analysis.
CONCLUSIONS: Mortality of patients with BP is more likely related to advanced age and associated medical conditions than to disease-specific factors.

Entities:  

Mesh:

Year:  2008        PMID: 18707800     DOI: 10.1016/j.jaad.2008.07.022

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 4.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

5.  Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors:  Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

6.  Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009.

Authors:  Katherine E Brick; Chad H Weaver; Christine M Lohse; Mark R Pittelkow; Julia S Lehman; Michael J Camilleri; Mustafa Al-Hashimi; Carilyn N Wieland
Journal:  J Am Acad Dermatol       Date:  2014-04-03       Impact factor: 11.527

7.  Specific causes of death in patients with bullous pemphigoid as measured by death certificate data: a retrospective cohort study.

Authors:  Benjamin J Barrick; Christine M Lohse; Julia S Lehman
Journal:  Int J Dermatol       Date:  2013-12-30       Impact factor: 2.736

8.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

9.  Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.

Authors:  Yi-Di Liu; Yan-Hong Wang; Yi-Cong Ye; Wen-Ling Zhao; Li Li
Journal:  Arch Dermatol Res       Date:  2017-03-19       Impact factor: 3.017

10.  Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea.

Authors:  Hyeon Woo Jeon; Sook Jung Yun; Seung-Chul Lee; Young Ho Won; Jee-Bum Lee
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.